As the only national nonprofit advocacy organization focused on hereditary breast and ovarian cancer, FORCE has a strong commitment to promoting research.
Study identifier: NCT01237067
Full study details on clinicaltrials.gov
Name of PARP Inhibitor used in study:
Patients with recurrent/refractory breast cancer that is metastatic or unresectable and for which standard therapies do not exist or are no longer effective. BRCA1/2 mutation carriers will be eligible with any metastatic disease.
Type of study:
Phase I study
Breast cancer patients who enroll will receive one of several possible schedules of olaparib plus carboplatin.
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892
Contact: Laura D.Otten, R.N., B.S.N., O.C.N.
Medical Oncology Referral Coordinator 301-451-1228
1-866-611-6310 (Toll Free) email@example.com